Pilot Study to Evaluate the Safety and Efficacy of 212Pb-VMT-a-peptide in Subjects With Somatostatin Receptor Expressing Neuroendocrine Tumors
- Conditions
- Health Condition 1: C17- Malignant neoplasm of small intestineHealth Condition 2: C7A8- Other malignant neuroendocrine tumors
- Registration Number
- CTRI/2023/10/059269
- Lead Sponsor
- B J Madan and Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1) Male or female =18 years old with unresectable or metastatic histologically confirmed NET
2) Documented progression of disease following previous therapy within 12 months prior to enrollment and the presence of at least 1 site of measurable disease per RECIST 1.1;
3) Subjects must have received and progressed following somatostatin analog administration.
4) Confirmed presence of somatostatin receptors on all lesions including the non-target and measurable lesions documented by CT/MRI scans, based on positive 68Ga- DOTANOC or Pb203-VMT-a-peptide SSTR PET/CT imaging within 6 weeks prior to enrollment. Follow up imaging will be performed with the same agent or modality used at baseline;
5) Target lesions must be positive (greater than grade 2 uptake Krenning Score) or must have an SUV of more than the normal liver background.
6) Lytic bone lesions, with an identifiable soft tissue component, evaluated by CT or MRI, can also be considered measurable lesions if the soft tissue component otherwise meets the definition of measurability according to RECIST 1.1. In any case, osteoblastic bone lesions are not measurable.
7) Eastern Cooperative Oncology Group (ECOG) status 0-2.
8) Life expectancy of at least 12 weeks in the opinion of the investigator at the time of screening;
9) Be willing to practice the following medically acceptable methods of birth control (both women of childbearing potential (WOCBP) and men who have partners of childbearing potential) from the Screening Visit through 3 months after the final administration 212Pb- VMT-a-peptide.
10) Sufficient bone marrow capacity and organ function in the recent blood tests within 3 weeks prior to Day 1, as defined by:
a) White blood cell (WBC) =2,500/ mm3;
b) Absolute neutrophil count (ANC) =1000/mm3;
c) Platelets =100,000/mm3;
d) Hemoglobin (HgB) =9.0 g/dL;
e) Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) =3 X upper limit of normal (ULN);
f) Total Bilirubin: =2 X ULN;
g) Serum creatinine =1.7 mg/dL;
h) Serum albumin =3.0 g/L; if lower than 3.0 g/L requires normal range prothrombin time (PT) and international normalized ratio (INR)
1) Prior whole-body radiotherapy or PRRT using 177Lu/90Y/111In-DOTATATE/ DOTATOC or TAT.
2) Prior regional hepatic radionuclide therapy within 4 months prior to enrollment or prior nonradioactive regional hepatic therapy within 6 months prior to enrollment.
3) Known hypersensitivity to somatostatin analogues, AA infusion, or 212Pb-VMT-a-peptide;
4) Therapeutic use of any somatostatin analogue, including Sandostatin® LAR (within 28 days) and Sandostatin® (within 1 day) prior to administration of study drug;
5) History of myelodysplastic syndrome (MDS);
6) Female subjects who are pregnant or lactating;
7) Indication for surgical lesion removal with curative potential;
8) Known brain metastases, unless these metastases have been treated and/or stable for 6 months prior to enrollment;
9) Experimental cancer treatments or other investigational therapies within 6 weeks or five half-lives of the investigational medication prior to Day 1;
10) Uncontrolled congestive heart failure (NYHA II, III, IV);
11) Uncontrolled diabetes mellitus as defined by a hemoglobin A1C >10.0;
12) Evidence of renal obstruction based on Tc-99m DTPA or TER for MAG3 renal scintigraphy or renal ultrasound.
13) Known or active human immunodeficiency virus (HIV) or hepatitis B or C virus unless cured;
14) Known or suspected active drug or alcohol abuse;
15) Participation in other interventional clinical studies within 30 days prior to Day 1;
16 Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and proven no evidence of recurrence for 5 years;
16) Any somatic or psychiatric disease/condition or abnormal laboratory test that in the opinion of the investigator, may interfere with the objectives and assessments of the study; or
17) Unable to comply with the requirements of the study protocol or be unsuitable for the study for any reason, in the opinion of the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method